294 related articles for article (PubMed ID: 31749092)
1. Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure.
Armstrong A; Paul C; Puig L; Boehncke WH; Freeman M; Torii H; Papp K; Griffiths CEM; Blauvelt A; Reich K; Gooderham M; Terui T; Renda L; Agada N; Xu W; Gallo G; Lebwohl MG
Dermatol Ther (Heidelb); 2020 Feb; 10(1):133-150. PubMed ID: 31749092
[TBL] [Abstract][Full Text] [Related]
2. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese MC; Mysler E; Tomita T; Papp KA; Salvarani C; Schwartzman S; Gallo G; Patel H; Lisse JR; Kronbergs A; Leage SL; Adams DH; Xu W; Marzo-Ortega H; Lebwohl MG
Rheumatology (Oxford); 2020 Dec; 59(12):3834-3844. PubMed ID: 32449924
[TBL] [Abstract][Full Text] [Related]
3. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
Strober B; Leonardi C; Papp KA; Mrowietz U; Ohtsuki M; Bissonnette R; Ferris LK; Paul C; Lebwohl M; Braun DK; Mallbris L; Wilhelm S; Xu W; Ljungberg A; Acharya N; Reich K
J Am Acad Dermatol; 2017 Mar; 76(3):432-440.e17. PubMed ID: 27889292
[TBL] [Abstract][Full Text] [Related]
4. Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure.
Griffiths CEM; Gooderham M; Colombel JF; Terui T; Accioly AP; Gallo G; Zhu D; Blauvelt A
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1431-1446. PubMed ID: 35624407
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.
Langley RG; Kimball AB; Nak H; Xu W; Pangallo B; Osuntokun OO; Agada N; Reich K
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):333-339. PubMed ID: 30198588
[TBL] [Abstract][Full Text] [Related]
7. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
8. Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.
Mease P; Roussou E; Burmester GR; Goupille P; Gottlieb A; Moriarty SR; Benichou O; Adams DH; Xu W; Nash P
Arthritis Care Res (Hoboken); 2019 Mar; 71(3):367-378. PubMed ID: 30156760
[TBL] [Abstract][Full Text] [Related]
9. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure.
Deodhar AA; Combe B; Accioly AP; Bolce R; Zhu D; Gellett AM; Sprabery AT; Burmester GR
Ann Rheum Dis; 2022 Jul; 81(7):944-950. PubMed ID: 35393269
[TBL] [Abstract][Full Text] [Related]
10. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis.
Combe B; Rahman P; Kameda H; Cañete JD; Gallo G; Agada N; Xu W; Genovese MC
Arthritis Res Ther; 2020 Jan; 22(1):14. PubMed ID: 31964419
[TBL] [Abstract][Full Text] [Related]
11. Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials.
Smith SD; Stratigos A; Augustin M; Carrascosa JM; Grond S; Riedl E; Xu W; Patel H; Lebwohl M
Dermatol Ther (Heidelb); 2023 Aug; 13(8):1773-1787. PubMed ID: 37351831
[TBL] [Abstract][Full Text] [Related]
12. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
Blauvelt A; Reich K; Papp KA; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaçi D; Li Q; Cichanowitz N; Green S; La Rosa C
Br J Dermatol; 2018 Sep; 179(3):615-622. PubMed ID: 29742274
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
Leonardi C; Reich K; Foley P; Torii H; Gerdes S; Guenther L; Gooderham M; Ferris LK; Griffiths CEM; ElMaraghy H; Crane H; Patel H; Burge R; Gallo G; Shrom D; Leung A; Lin CY; Papp K
Dermatol Ther (Heidelb); 2020 Jun; 10(3):431-447. PubMed ID: 32200512
[TBL] [Abstract][Full Text] [Related]
14. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
Reich K; Papp KA; Griffiths CE; Szapary PO; Yeilding N; Wasfi Y; Ott E; Hsu MC; Lebwohl M; Gordon KB;
J Drugs Dermatol; 2012 Mar; 11(3):300-12. PubMed ID: 22395580
[TBL] [Abstract][Full Text] [Related]
15. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB; Blauvelt A; Papp KA; Langley RG; Luger T; Ohtsuki M; Reich K; Amato D; Ball SG; Braun DK; Cameron GS; Erickson J; Konrad RJ; Muram TM; Nickoloff BJ; Osuntokun OO; Secrest RJ; Zhao F; Mallbris L; Leonardi CL; ; ;
N Engl J Med; 2016 Jul; 375(4):345-56. PubMed ID: 27299809
[TBL] [Abstract][Full Text] [Related]
16. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.
Papp KA; Bachelez H; Blauvelt A; Winthrop KL; Romiti R; Ohtsuki M; Acharya N; Braun DK; Mallbris L; Zhao F; Xu W; Walls CD; Strober B
Br J Dermatol; 2017 Dec; 177(6):1537-1551. PubMed ID: 28600810
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
[TBL] [Abstract][Full Text] [Related]
18. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
Reich K; Leonardi C; Langley RG; Warren RB; Bachelez H; Romiti R; Ohtsuki M; Xu W; Acharya N; Solotkin K; Colombel JF; Hardin DS
J Am Acad Dermatol; 2017 Mar; 76(3):441-448.e2. PubMed ID: 28027825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
